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Background.Low clearance transplant clinics (LCTCs) are recommended for themanagement of recipientswith a failing kidney
transplant (RFKT) but data to support their use is limited.We conducted a retrospective study to assessmanagement of RFKTat 2
transplant centers, 1 with a LCTC (center A) and 1 without (center B).Methods.Patients who transitioned to an alternative form
of renal replacement therapy (RRT) between January 1, 2012, and November 30, 2016, were included. Patients with graft failure
within a year of transplantation or due to an unpredictable acute event were excluded. Clinical data were collected after review of
medical records. Results. One hundred seventy-nine patients (age, 48.6 ± 13.4 years, 99 [55.3%] male, and mean transplant
duration 10.3 ± 7.8 years) were included. RRT counseling occurred in 79 (91%) and 68 (74%) patients at centers A and B
(P = 0.003), at median 135 (61-319) and 133 (69-260) days before dialysis after graft loss (P = 0.92). Sixty-one (34.1%) patients were
waitlisted for retransplantation; 18 (32.7%) nonwaitlisted patients were still undergoingworkup at center A comparedwith 37 (58.7%)
at center B (P = 0.028). Preemptive retransplantation occurred in 4 (4.6%) and 5 (5.4%) patients at centers A and B (P = 0.35). At
1 year after initiation of dialysis after graft loss, 11 (15.3%) and 11 (17.2%) patients were retransplanted (P = 0.12), and mortality
was 6.6% overall. Conclusions. A dedicated LCTC improved RRT counseling and transplant work-up but did not lead to im-
proved rates of retransplantation. Earlier consideration of retransplantation in LCTCs is required to improve RFKToutcomes.
(Transplantation Direct 2018;4:e352; doi: 10.1097/TXD.0000000000000788. Published online 2 May, 2018.)K idney transplant recipients (KTRs) returning to dialysisafter graft loss (DAGL)make up around 4% of the inci-
dent dialysis population, andDAGL is now in the top 5 reasons
for the initiation of dialysis overall.1-3 Although short-termReceived 21 February 2018.
Accepted 9 March 2018.
1 Center for Nephrology, University College London (UCL), London, UnitedKingdom.
2 Bart’s Health NHS Trust, London, United Kingdom.
3 Royal Free Hospital NHS Trust, London, United Kingdom.
The authors declare no funding or conflicts of interest.
R.E., G.J., and R.T. designed the study. R.E., S.B., S.G.C., S.M.C., L.H., and A.T.
collected and analyzed the data. R.E., G.J., and R.T. drafted the article. All authors
have reviewed and critically appraised the content of the article and approved it
for publication.
Correspondence: Rhys D.R. Evans MA MBBS MRCP(Neph), UCL Center for
Nephrology, Royal Free Hospital, Pond Street, London, NW3 2QG, United Kingdom.
(rhys.evans@ucl.ac.uk; rhysdrevans@gmail.com).
Copyright © 2018 The Author(s). Transplantation Direct. Published by Wolters
Kluwer Health, Inc. This is an open-access article distributed under the terms of
the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0
(CCBY-NC-ND), where it is permissible to download and share the work provided
it is properly cited. The work cannot be changed in any way or used commercially
without permission from the journal.
ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000000788
Transplantation DIRECT ■ 2018outcomes in graft survival have improved significantly in re-
cent years, there has been a more modest improvement in
longer-term survival.4,5 Kidney transplant recipients with re-
nal function that is approaching end stage are termed recip-
ients with a failing kidney transplant (RFKT). Despite
offering the best outcomes, only a minority of RFKT gets
retransplanted and with transplant being the most preva-
lent form of renal replacement therapy (RRT), the number
of patients requiring DAGL is likely to increase.6
There is evidence that RFKT get worse care than those
with native disease.7,8 Moreover, patient outcomes during
the period of worsening graft function is poor, and as esti-
mated glomerular filtration rate (eGFR) declines, there is an
associated increase in cardiovascular events and death.9 Pa-
tient outcomes are even worse when RFKT return to dialy-
sis with mortality higher compared with similar patients
awaiting transplant for the first time.10 Mortality on DAGL
is 16% at 1 year and 33% at 3 years, most commonly due
to cardiovascular disease, infection, and cancer.11,12
RFKTare therefore a high-risk cohort in whom there may
be opportunities to improve care. Moreover, the switch from
transplant to other forms of RRT can be a psychologically
challenging time, highlighting the need for augmented sup-
port of this vulnerable group. The British Transplantation
Society recommend managing RFKT in dedicated transplantwww.transplantationdirect.com 1
2 Transplantation DIRECT ■ 2018 www.transplantationdirect.comclinics termed low-clearance transplant clinics (LCTC).1
However, evidence to support this practice is limited, and
the benefit of such clinics is unknown. Accordingly, we un-
dertook a retrospective study of the management of RFKT
at 2 UK transplant centers, 1 with a dedicated LCTC, and an-
other without.MATERIALS AND METHODS
Study Design and Setting
We conducted a retrospective, cohort study at Bart’s Health
(center A) and Royal Free Hospital (center B) NHS Trusts.
Both centers provide tertiary nephrology and kidney trans-
plant services to northeast and north central London and their
surrounding regions respectively. The populations served by
both centers are ethnically and socioeconomically diverse;
264 kidney transplants were performed across the sites be-
tween April 1, 2016, and March 31, 2017.13
Center A established a dedicated centralized LCTC in 2007.
This provides multidisciplinary care to transplant patients
with eGFR less than 30mL/min per 1.73m2. Patients are pri-
marily reviewed by nephrologists, but also have access to
transplant nurses specifically trained in the management of
the complications of advanced chronic kidney disease (CKD),
renal dieticians, and specialist renal pharmacists. There is a clin-
ical focus on preparing patients for retransplantation and
DAGL. Center B manages chronic transplant patients within
the same clinic regardless of the degree of renal impairment.
Patients are reviewed in both centralized and peripheral clinics.
Patients in center B also have access to multidisciplinary ser-
vices, equivalent to center A, but notwithin a dedicated LCTC.
Participants
Transplant patients who transitioned to an alternative form
of RRT (hemodialysis, peritoneal dialysis, retransplantation,
or conservative management) between December 1, 2012,
and November 30, 2016 were included. Patients who died
with a functioning graft, who transitioned within the first
year of transplantation, or in whom graft loss was due to
an unpredictable acute event as determined by the study
team were excluded.
Data Collection
Patients were identified and data collected from electronic
medical records at both sites. The following were recorded
for each patient:
(A) Demographic and baseline clinical data;
(B) Details of CKD parameters and their management.
Including hemoglobin, serum creatinine, urea, bicarbonate,
calcium, phosphate, parathyroid hormone, blood pressure and
theirmanagement (erythropoietin, phosphate binder, alphacalcidol,
and sodium bicarbonate use). The last values measured before
the initiation of DAGL were recorded.
(C) Details of the initiation of DAGL
Including documentation and timing of RRTcounseling, modal-
ity restarted and location of restart (acute admission vs planned),
retransplant wait listing and reason if not, and dialysis access
at the time of restart.
(D) Patient outcomes at 1 year after RRT transitionIncluding survival and RRT modality at this time point.
For each site, mean values at the initiation ofDAGL for each
CKDparameter were determined, in addition to the number of
patientsmanagedwith erythropoietin, bicarbonate supplemen-
tation, a phosphate binder, and activated vitamin D. The pres-
ence and timing of RRT counseling, the numbers of patients
listed for retransplantation, preemptive retransplantation rates,
and access for dialysis were calculated at each center. Unad-
justedmortality andRRTmodalities at 1 yearwere determined
at both sites.
Outcome Measures
The primary outcome measure was the rate of preemptive
retransplantation. Secondary outcomes were an assessment
of CKDmanagement in RFKT, the presence of RRTcounsel-
ing, listing for retransplantation at the time of initiation of
DAGL, and 1 year retransplantation and mortality rates.
Statistical Analysis
Variables are presented as either mean ± standard devia-
tion (SD) or median ± interquartile range dependent on data
distribution. Variables were compared between center A and
center B using the Student t test and Mann-Whitney test if
continuous, and using tests of proportionality (Fisher exact
or χ2) if categorical. We compared 1-year unadjusted mortal-
ity between centers, using a log rank test to examine for differ-
ences in survival between these groups. Patients managedwith
conservative care (ie, not considered for retransplantation or
dialysis) were excluded from the outcome analysis.
All analyses were conducted with Graphpad Prism version
7, with a P value less than 0.05 considered to represent statis-
tical significance.RESULTS
Participants
Graft failure or death with a functioning graft occurred in
426 patients during the study period. Predictable graft failure
1 year ormore after transplantation occurred in 179 patients,
and these patients were included in the study (Figure 1).
Descriptive Data
Demographic and baseline clinical data are summarized in
Table1.Meanageat initiationofDAGLwas48.6±13.4years,
99 (55.3%) patients were male, andmean transplant duration
was 10.3 ± 7.8 years. The most common causes of end-stage
renal disease were unclear/small kidneys (n = 33, 18.4%), con-
genital kidney disease/reflux nephropathy (n = 27, 15.1%),
hypertensive kidney disease (n = 23, 12.8%), IgA nephropa-
thy (n = 19, 10.6%), and focal segmental glomerulosclerosis
(n = 14, 7.8%).
In 67 (34.0%) patients, the cause of allograft loss was un-
determined. The cause of graft loss was made by biopsy diag-
nosis in 43 (49.4%) patients at center A and 52 (56.5%)
patients at center B (P = 0.37). The most common causes of
biopsy proven allograft loss were chronic rejection/transplant
glomerulopathy (n = 32, 16.2%), interstitial fibrosis and tubu-
lar atrophy (n = 29, 14.7%), and recurrent disease (n = 20,
10.2%). There were significant differences in the causes of al-
lograft loss between the sites, but not in other demographic
or clinical parameters.
FIGURE 1. Cohort description.
TABLE 1.




(n = 92) P
Demographics
Mean (SD) age at restart 49.7 (12.0) 47.6 (14.5) 0.29
Sex (n; % male) 52 (59.8) 47 (51.1) 0.29
Transplant details
Live donor 29 (33.3) 24 (26.1) 0.37
Deceased donor 58 (66.7) 67 (72.8)
Unclear 0 (0.0) 1 (1.1)
Transplant duration
Mean (SD), y 9.5 (7.6) 10.6 (8.0) 0.32
Cause of end-stage renal disease, number (%)
Unclear/small kidneys 21 (24.1) 12 (13.1) 0.24
Hypertension 12 (13.8) 11 (12.0)
IgA nephropathy (including Henoch-Schonlein purpura) 10 (11.5) 9 (9.8)
Focal segmental glomerulosclerosis 7 (8.1) 7 (7.6)
Membranoproliferative glomerulonephritis 7 (8.1) 6 (6.5)
Congenital kidney disease/reflux nephropathy 7 (8.1) 20 (21.7)
Diabetes mellitus 6 (6.8) 6 (6.5)
Other 17 (19.5) 21 (22.8)
Cause of allograft loss, n (%)
Unclear/chronic decline in kidney function (no biopsy) 42 (48.3) 25 (27.2) 0.005
Chronic rejection/transplant glomerulopathy
(biopsy proven)
10 (11.5) 22 (23.9)
Scarred kidney/interstitial fibrosis and tubular atrophy
(biopsy proven)
17 (19.5) 12 (13.0)
Recurrent disease 7 (8.0) 13 (14.1)
Chronic pyelonephritis/obstruction/UTIs 2 (2.3) 7 (7.6)
BK nephropathy 5 (5.7) 1 (1.1)
Calcineurin inhibitor toxicity 3 (3.4) 1 (1.1)
Posttransplant lymphoproliferative disease 1 (1.1) 1 (1.1)
Other 0 (0.0) 10 (10.9)
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CKD Parameters at Restart
Table 2 outlines clinical and biochemical CKD parameters
at the initiation of DAGL. Mean hemoglobin was lower in
center A (89.4 ± 15.3 g/L) than center B (96.1 ± 17.1 g/L;
P = 0.007). Diastolic blood pressure was better controlled
in center A (81 ± 15 mm Hg) than center B (86 ± 13 mm Hg;
P = 0.019). Alphacalcidol was used more frequently at center
B (33 (37.9%) versus 59 (64.1%) patients; P = 0.0006), al-
though this did not impact on phosphate or parathyroid hor-
mone levels. There were no other statistically significant
differences between the sites.
In centers A and B, respectively, hemoglobin was 100 g/L
or greater in 25 (28.7%) and 34 (36.9%) patients (P = 0.27),
phosphate was 1.5 mmol/L or less in 31 (35.6%) and 35
(38.0%) patients (P = 0.76), and bicarbonate was 22 mmol/LTABLE 2.
Clinical and biochemical parameters at restart, and CKD
management before DAGL
Center A (n = 87) Center B (n = 92) P
Parameter at restart, mean (SD)
Hemoglobin, g/L 89.4 (15.3) 96.1 (17.1) 0.007
Phosphate, mmol/L 1.69 (0.46) 1.77 (0.52) 0.28
Parathyroid hormone, pmol/L 52.2 (44.6) 41.8 (36.7) 0.09
Bicarbonate, mmol/L 19.5 (3.5) 19.8 (4.6) 0.64
Creatinine, μmol/L 626 (225) 675 (302) 0.22
Urea, mmol/L 30 (9) 30 (11) 0.63
Systolic BP, mm Hg 147 (27) 146 (22) 0.68
Diastolic BP, mm Hg 81 (15) 86 (13) 0.019
CKD management, n (%)
Erythropoietin used 61 (70.1) 66 (71.7) 0.87
Phosphate binder used 23 (26.4) 15 (16.3) 0.10
Alphacalcidol used 33 (37.9) 59 (64.1) 0.0006
Bicarbonate supplementation 55 (63.2) 64 (69.6) 0.43
FIGURE 2. Kaplan-Meier survival analysis censored at 1 year com-
paring center A and center B. Probability of survival was greater at
center B (log rank test P = 0.0248).
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tiation of DAGL.
Median eGFRat initiation ofDAGLwas 7.75 (6.0-10.0)mL/
min per 1.73 m2 at center A and 7.43 (5.7-10.3) mL/min per
1.73 m2 at center B (P = 0.30).
Initiation of DAGL
Renal replacement therapy counseling was documented in
147 (82.1%) patients, but more so in center A than center B
(79 [90.8%] vs 68 [73.9%] patients; P = 0.0034). If patients
underwent RRT counseling, it occurred at a median 135
(61-319) days before restart at center A and 133 (69-260)
days before restart at center B (P = 0.92).
Modalities ofRRTrestarted and vascular access in hemodial-
ysis patients are outlined in Table 3. A total of 9 (5.0%) patients
across both sites underwent preemptive retransplantation (cen-
ter A, n = 4 [4.6%]; center B, n = 5 [5.4%], P = 0.35). Renal
replacement therapy was restarted as an acute admission in
32 (38.6%) patients at center A, and 43 (49.4%) patients
in center B (P = 0.33).
Sixty-one (34.1%) patients were waitlisted for transplant
at the time of restart. There were significant differences in
the reasons for not wait listing patients between centers,
with more patients undergoing workup and deemed medi-
cally unfit at center A (n = 22 [40.0%] center A; n = 14
[22.2%] center B), and more patients still undergoing
work-up at center B (n = 18 [32.7%] center A; n = 37
[58.7%] center B) (P = 0.028, Table 3).
1-Year Patient Outcomes
One hundred thirty-six patients completed 1 year of
follow-up after changing modality and were included in the
outcome analysis. The number of patients managed withTABLE 3.
RRT modality restarted, location of initiation of DAGL
(transplants excluded), hemodialysis access, and details
of transplant relisting at the initiation of DAGL
Center A (n = 87) Center B (n = 92) P
RRT modality restarted
Hemodialysis 70 (80.5) 70 (76.1) 0.35
Peritoneal dialysis 11 (12.6) 17 (18.5)
Retransplant (preemptive) 4 (4.6) 5 (5.4)
Supportive 2 (2.3) 0 (0.0)
Location of initiation of DAGL, n (%)
Acute admission 32 (38.6) 43 (49.4) 0.32
Outpatient (planned) 49 (59.0) 43 (49.4)
Unclear 2 (2.4) 1 (1.1)
Hemodialysis access, n (%)
Tunnulled or nontunnelled catheter 33 (47.1) 36 (51.4) 0.1
AVF 31 (44.3) 34 (48.6)
Arteriovenous graft 4 (5.7) 0 (0.0)
Unclear 2 (2.9) 0 (0.0)
Transplant relisting, n (%)
Listed at time restart 32 (36.7) 29 (31.5) 0.53
Reason not waitlisted, n (%)
Considered but medically unfit 22 (40.0) 14 (22.2) 0.028
Considered and still working up 18 (32.7) 37 (58.7)
Not clear or no documentation 11 (20.0) 11 (17.5)
Patient choice 3 (5.5) 0 (0.0)
Deliberate (imminent live donor) 1 (1.8) 1 (1.6)hemodialysis, peritoneal dialysis, and transplanted at this
point was 48 (66.7%), 5 (6.9%), and 11 (15.3%) at center
A, and 44 (68.8%), 8 (12.5%), and 11 (17.2%), at center
B, respectively (P = 0.12). The number of hemodialysis pa-
tients with an arteriovenous fistula (AVF) at 1 year was 27
(56.3%) at center A and 39 (88.6%) at center B (P = 0.0019).
The crude 1-year mortality rate was 6.6% (n = 9) across
both sites (Figure 2). Death occurred at a mean time of
132 ± 112 days after initiation of DAGL. Causes of
death were unclear (n = 5, 55.6%), malignancy, including
posttransplant lymphoproliferative disease (n = 3, 33.3%),
and stroke (n = 1, 11.1%).DISCUSSION
Key Findings
In this retrospective study, we assessed the management of
179 RFKT at 2 transplant centers in London, UK, 1 with a
dedicated LCTC (center A), and 1 without (center B). Docu-
mented RRT counseling and retransplant workup was greater
in centerA, but this didnot translate in to better retransplantation
rates. Preemptive retransplantation occurred in 4 (4.6%) and
5 (5.4%) patients, and retransplantation at 1 year in 11
(15.3%) and 11 (17.2%) patients in centers A and B, respec-
tively. At initiation of DAGL mean hemoglobin and blood
pressure were 89.4 g/l and 147/81 mmHg at center A, and
96.1 g/l and 146/86 mmHg at center B, but there were no
other differences in CKD parameters. Crude 1-year mortality
was 6.6% overall, worse in center A than center B.
Interpretation
Advanced renal impairment is common in KTRs and 18%
of transplant patients have an eGFR less than 30 mL/min per
1.73 m2 in the United Kingdom.8 RFKT are a high-risk co-
hort and the management of these patients in LCTCs is rec-
ommended.1 Such clinics cohort patients with advanced
renal impairment and prioritize management of CKD com-
plications, and preparation for retransplantation andDAGL.
To the best of our knowledge, this is the first study to investi-
gate the value of this approach.
RFKT are a unique and complex group of patients. Their
management is challenging and must balance ongoing efforts
to maximize current graft survival, managing the conse-
quences of advanced renal impairment, andmaking decisions
with regards to retransplantation and DAGL. It is a psycho-
logically difficult time for patients with increased rates of de-
pression and anxiety.14 Furthermore, the increased risk of
© 2018 Wolters Kluwer Evans et al 5cardiovascular disease, infection, and malignancy associated
with prolonged immunosuppression must be addressed. Pa-
tient outcomes worsen as renal function declines in KTRs,
and for each 5 mL/min per 1.73 m2 loss of GFR below an
eGFR of 45 mL/min per 1.73 m2, there is a 15% increased
risk of death.9 However, RFKT are relatively young; mean
age was 48.6 years at initiation of DAGL in this study, youn-
ger than patients starting dialysis more generally, and there-
fore focusing efforts to improve care in this cohort may
have potentially significant long-term consequences.
Management of the complications of advanced CKD is an
important aspect of care in LCTCs. Guidelines recommend
that blood pressure be controlled to less than 130/80 mm Hg
(<125/75 mm Hg if proteinuria) given its beneficial effect on
cardiovascular outcome, but there are no transplant-specific
targets for management of anemia, CKD-mineral bone disor-
der, or acidosis, and clinical decisions are based on guidance
for the native CKD population.1 Previous reports have
highlighted deficiencies in the management of CKD complica-
tions in RFKT,8,15 and despite management in a dedicated
LCTC, data from this study supported this finding. Mean
hemoglobin, phosphate, and bicarbonate levels at initiation
of DAGL at center A were 89.4 g/L, 1.69 mmol/L, and
19.5 mmol/L, respectively, as compared with values of 113 g/L,
1.65 mmol/L, and 20.3 mmol/L, in a cohort of CKD 5 T pa-
tients in Spain.15 Although some of the deficiency in man-
agement may be explained by our recording of the last
CKD parameter before dialysis restart as opposed to values
from amore stable CKD5T population, further efforts must
be made both in clinic and at postclinic multidisciplinary
transplant meetings to address these parameters and re-
search undertaken to investigate whether improved con-
trol translates in to improved outcome specifically in the
transplant setting.
There is conflicting evidence about when to restart
DAGL,12,16,17 but, akin to the native setting, there is a sug-
gestion of worse outcomes if dialysis is started early.12,17
Themedian eGFR in all patients at initiation of DAGL in this
study was 7 mL/min/1.73 m2, reflecting current standard UK
practice, and advice to start dialysis when eGFR falls to less
than 6 mL/min/1.73 m2 even if asymptomatic.1 Initiation of
DAGL should be planned, and 49.4% of patients in the cen-
ter without a dedicated LCTC restarted dialysis via an acute
admission. This has potentially adverse consequences for pa-
tients themselves, and also adds pressure to service provision
within the health system more generally.
Although needing to be assessed on a case-by-case basis, of
less debate is the optimal modality of RRTafter allograft fail-
ure. Retransplantation, especially if preemptive, offers clear
advantages in terms of quality of life and survival.3,18,19
Retransplantation was associated with a 45% and 23% re-
duction in 5-year mortality in diabetic (type 1) and nondia-
betic kidney disease in the United States,3 and with an 88%
reduction in overall mortality during 12 years follow-up in
the United Kingdom.18 Preemptive retransplantation is rec-
ommended in RFKT when eGFR falls to 10 to 15 mL/min
per 1.73 m2.1 In this study, retransplantation rates were
low, with 5.0% of patients preemptively retransplanted and
16.2% of patients retransplanted at 1 year across both cen-
ters. This compares to previously reported preemptive trans-
plant rates of 2.6% in Northern Ireland,18 and 15% to 29%
retransplant rates at 5 years in the United States.3Retransplantation requires early discussion of RRT op-
tions after allograft failure, in particular as rapid graft failure
is commonly encountered as transplant patients approach
end stage.18 For this reason, in addition to the other complex-
ities surrounding retransplant workup outlined below, a rela-
tively high eGFR cut off of 30 mL/min per 1.73 m2 was
chosen for LCTC referral at center A. Admission that an allo-
graft is failing may be a difficult process for both patients and
healthcare professionals alike, and one of the key roles of a
LCTC is to change expectations of the clinical interaction
from one focused primarily on current graft survival to pre-
paring for RRT after allograft loss. In the center with a dedi-
cated LCTC, RRT counseling occurred more frequently;
however, this occurred at a median time of between only 4
and 5 months before initiation of DAGL. The improved
counseling, and indeed subsequent transplant workup in cen-
ter A, did not translate in to improved preemptive retransplant
rates and this delayed timing is likely to be the critical factor.
Other challenges specific to retransplantation may have also
impacted rates, including increased comorbidity (40% of pa-
tientswere deemedmedically unfit for retransplantation at cen-
ter A), increased allosensitization, surgical complexities, and
concerns of increased risk of recurrent disease if this was cause
of initial allograft loss. This further emphasizes the need for
early referral to LCTCs and subsequent retransplant work-up.
Aside from retransplantation, hemodialysis and peritoneal
dialysis provide equivalent outcomes in RFKT,2 and deci-
sions regarding modality are the same as in native kidney dis-
ease.20 Overall, 78.2% of patients in this study were treated
with hemodialysis at restart compared with 15.6%with peri-
toneal dialysis; this compares to equivalent RRT rates of
73.1% and 19.2% of all dialysis starts in the United
Kingdom in 2015.21 Approximately half of hemodialysis pa-
tients started dialysis with definitive access (ie, an AVF or
graft) in this study, better than reported rates from North
America.22,23 The presence of an access surgeon within the
LCTC may improve this further, but must be balanced with
the implications on resources available for other surgical
work. Dialysis should start in a planned fashion, and the fact
that 59% of patients in center B started dialysis via an acute
admission highlights some deficiencies in planning and out-
patient care. Lessons may be learned from the native low
clearance setting, wheremore established protocols including
early documented RRT and access plans exist.
1-year survival was better at both centers than published
estimates.12 Death occurred in 9 patients overall, and in only
1 patient in center B. Given these low numbers, firm conclu-
sions comparing the centers are difficult to make. This low
mortality rate may reflect improved dialysis care, including
the recognition in the centers studied that patients in the ini-
tial period on dialysis after allograft loss are high risk and re-
quire more intensive follow-up.
Strengths and Limitations
This study assessed the value of LCTCs in themanagement
of RFKT. It highlights the value of collaborative research be-
tween transplant centers in the UK, and a relatively large co-
hort of patients was included with complete data in most.
Although undertaken only in London, the findings are appli-
cable to other settings within the region.
A center with a LCTC and 1 without were compared. Po-
tential differences (eg, ethnic and socioeconomic) in the
6 Transplantation DIRECT ■ 2018 www.transplantationdirect.compopulations served by each center and other variables in care
aside from the presence of a LCTCmay explain center differ-
ences in practices and outcomes, and no attemptwasmade to
adjust for these. The study was retrospective and observa-
tional, and some datawasmissing including details surround-
ing RRT counseling, the exact timing of this, and causes of
death. Not all patients who transitioned to conservative care
may have been captured, as modality may not have been
changed on the electronic record. We assessed blood pressure
control in RFKT, but did not collect data on other cardiovas-
cular targets such as smoking and lipid control. Similarly, we
did not record other aspects of care and outcomes after allo-
graft loss, such as details onmanagement of immunosuppres-
sion, graft nephrectomy, and sensitization rates.
CONCLUSIONS
Adedicated LCTC improved RRTcounseling, reduced un-
planned dialysis starts and increased retransplant workup
but this did not translate in to improved rates of preemptive
retransplantation, retransplant waitlisting, or 1-year survival.
Altering patient and clinician expectations in LCTCs coupled
with earlier consideration of retransplantation and DAGL
are required to improve retransplantation rates and out-
comes in this high-risk cohort.
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